WO2006118364A1 - COSMETIC COMPOSITION CONTAINING (20S)-GINSENOSIDE Rg3 FOR PREVENTING AND IMPROVING SKIN WRINKLES - Google Patents
COSMETIC COMPOSITION CONTAINING (20S)-GINSENOSIDE Rg3 FOR PREVENTING AND IMPROVING SKIN WRINKLES Download PDFInfo
- Publication number
- WO2006118364A1 WO2006118364A1 PCT/KR2005/002298 KR2005002298W WO2006118364A1 WO 2006118364 A1 WO2006118364 A1 WO 2006118364A1 KR 2005002298 W KR2005002298 W KR 2005002298W WO 2006118364 A1 WO2006118364 A1 WO 2006118364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginsenoside
- skin
- cosmetic composition
- ginseng
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B24—GRINDING; POLISHING
- B24B—MACHINES, DEVICES, OR PROCESSES FOR GRINDING OR POLISHING; DRESSING OR CONDITIONING OF ABRADING SURFACES; FEEDING OF GRINDING, POLISHING, OR LAPPING AGENTS
- B24B37/00—Lapping machines or devices; Accessories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B24—GRINDING; POLISHING
- B24B—MACHINES, DEVICES, OR PROCESSES FOR GRINDING OR POLISHING; DRESSING OR CONDITIONING OF ABRADING SURFACES; FEEDING OF GRINDING, POLISHING, OR LAPPING AGENTS
- B24B47/00—Drives or gearings; Equipment therefor
Definitions
- the present invention relates to a cosmetic composition for preventing and improving skin wrinkles comprising 20(S)-ginsenoside Rg3, and more particularly to a cosmetic composition comprising 20(S)-ginsenoside Rg3, which is superior in proliferating fibroblasts, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent and improve skin wrinkles.
- Vitamin A retinol
- retinyl palmitate are commonly used as cosmetic compounds for preventing and improving skin wrinkles.
- cosmetics comprising these compounds may easily deteriorate with time, and may also cause serious skin irritation when they are penetrated or absorbed into the skin exceeding their effective amounts.
- Panax Ginseng (briefly 'Ginseng' hereinafter) is a medicinal herb belonging to Araliaceae family, which has been widely used in oriental medicine and also folk remedies.
- the ginseng is largely divided into three different kinds according to the status as green, white and red ginseng.
- White ginseng is prepared by removing rootlets of green ginseng (i.e. undried ginseng) followed by drying under the sun.
- Red ginseng is prepared by steaming the white ginseng.
- Saponin in ginseng is known to have an anti-oxidizing effect by promoting secretion of catecholamine in adrenal gland and inhibiting lipid peroxidation, along with other effects of protecting against radioactive rays, preventing abnormalities or micronuclei caused by alkylating agents, and lowering mutations in culturing cells.
- main active ingredients of ginseng are saponin ginsenosides.
- green ginseng, white ginseng and red ginseng commonly contains 18 compounds of Ro, Ra 1 , Ra2, Ra3, Rb 1 , Rb2, Rb3, Rc, Rd, Re, Rf, Rg 1 , Rg2, Rg3, Rhi, 2OgIc-Rf, Q-R 1 and N-R 1 as active ingredients.
- 4 compounds of Malonyl-Rbi, Malonyl-Rb2, Malonyl-Rcand and Malonyl-Rd are contained only in green ginseng and white ginseng
- 8 compounds of Rs 1 , Rs2, Rg3(S), Rh2, N-R 4 , Rg2(R), Rh 1 (R) and Rh 4 are contained only in red ginseng.
- ginseng saponin may be divided into panaxadiol-type ginsenosides (Ra 1 , Ra2, Ra3, Rb 1 , Rb2, Rb3, Rc, Rd and Rg3) / ginsenosides (Re, Rf, Rgi and Rg 2 ) and oleanolic acid-type ginsenosides.
- Ginseng roots comprise 48-60% of panaxadiol-type saponin, 30-35% of panaxatriol-type saponin and small quantity of oleanolic acid-type saponin.
- Rg3 One of minor ginsenosides, is produced during the process of steaming ginseng.
- a few patents have already disclosed that Rg3 has activities of inhibiting cancer cell metastasis, inhibiting platelet aggregation, inducing vasorelaxation, decreasing tolerance to anticancer drugs, inhibiting experimental liver damage and antithrombotic activity.
- the pharmaceutical activities in the aforementioned patents were restricted to orally administered Rg3, and there has been no report about the activities of topically applied Rg3 for improving skin wrinkles.
- ginsenoside Rg3 is extracted and separated from ginseng by extracting crude saponin with an organic solvent and condensing the crude saponin, followed by separation with silica gel or repeated purification with preparative liquid chromatography.
- the extracts also comprise saponin compounds in ginsenoside Rg family, having very similar molecular weight and physiochemical properties, which remains in small quantity even after the final purification.
- the yield of ginsenoside Rg3 is not so high and the repeated purification process for high purity requires a considerable amount of time and cost.
- the biotransformation process using acidic and basic hydrolysis and glycosidase still bring us other problems such as complexity in purification process and remnant solvents.
- ginsenoside aglicone C-20 position The glycosidic bonds on the structurally unstable ginsenoside aglicone C-20 position are easily cleaved by hydrolysis by performing heating and steaming ginseng thus expediting brown change, and C-20(S) and C-20(R) isomers may be produced as hydroxyl group causes inversion equilibrium.
- characteristic components Rh 1 , Rh 2 , Rs 1 , Rs 2 , Rg3, and Rgs
- minor ginsenosides may be extracted by heating or steaming ginseng.
- ginsenoside Rg3, a prosapogenin is contained more than 50 times of that in green ginseng or white ginseng.
- ginsenoside Rg3 has an activity of improving skin wrinkles, and filed a patent application claiming cosmetic composition comprising ginsenoside Rg3 (KR patent application no. 2003-65882).
- the skin improvement may be further accomplished by controlling the amount of ginsenoside Rg3 and the ratio of SR isomers to a specific range.
- the present inventors found that the effects of proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds vary depending on the amount of ginsenoside Rg3 and the ratio of 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3. More specifically, the present inventors found the aforementioned effects may be maximized by controlling the amount of 20(S)-ginsenoside Rg3 to 40-80 wt% and as the purity of S isomer increase up to 100%, thus completing the present invention.
- a cosmetic composition for preventing or improving skin wrinkles which comprises 20(S)-ginsenoside Rg3.
- the present invention relates to a cosmetic composition for preventing or improving skin wrinkles, which comprises 20(S)-ginsenoside Rg3 as active ingredient.
- the present invention relates to a cosmetic composition
- a cosmetic composition comprising 20(S)-ginsenoside Rg 3 , which is superior in proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent or improve skin wrinkles.
- the skin improvement effect varies depending on the amount of ginsenoside Rg 3 and the ratio of 20(S)-ginsenoside Rg 3 and 20(R)-ginsenoside Rg 3 , which are prepared from ginseng by acidic hydrolysis extraction method.
- the amount of 20(S)-ginsenoside Rg 3 is preferred to be in the range of 40-80 wt %.
- the effects are weakened when the amount is below 40 wt%, whereas the amount of above 80 wt% would incur high cost during the extraction and purification.
- the side effect of the ginseng-derived ginsenoside Rg3 is lower than any other synthetic material, and the skin toxicity test also showed that the extract herein has no harmful effect on the skin.
- the ginseng-derived ginsenoside Rg3 when applied to cosmetics, may be formulated into skin softeners, astringents, lotions, essence, creams, gels, packs, soaps, essence sheets, hydrogel patches or masks.
- the ginseng-derived ginsenoside Rg3 is preferred to be comprised in the amount of 0.000001-20.0 wt% with respect to the total cosmetic composition. The aforementioned effects may not be obtained when the amount is below 0.000001 wt%, however, when the amount is above 20 wt% the effect of improvement may not be satisfactory considering the increase in the amount and the formulation may be unstable.
- Figure 1 is a HPLC result of 20(S)-ginsenoside Rg3 prepared in Example 1.
- Figure 2 is a photograph of skin of hairless mouse after inducing artificial wrinkles.
- Figure 3 is a photograph showing the effect of improving wrinkles after applying 2500 IU/ g of retinol for two weeks.
- Figure 4 is a photograph showing the effect of improving wrinkles after applying 0.01 % of specimen 9 prepared in Example 2 for two weeks.
- Figure 5 is a photograph showing the effect of improving wrinkles after applying 0.01% of the extracts of Example 1 for two weeks.
- Figure 6 is a photograph showing the effect of improving elastic fiber after applying negative control group for two weeks.
- the black stripe is elastic fiber.
- Figure 7 is a photograph showing the effect of improving elastic fiber after applying 2500 IU/ g of retinol for two weeks.
- Figure 8 is a photograph showing the effect of improving elastic fiber after applying specimen 9 prepared in Example 2 for two weeks.
- Figure 9 is a photograph showing the effect of improving elastic fiber after applying the compound prepared in Example 1 for two weeks.
- Figure 10 is a photograph showing the effect of improving collagen cells after applying a negative control group for two weeks.
- the blue part is collagen
- the dark brown is cell nucleus
- the red is cytoplasm/ muscle/ keratin.
- Figure 11 is a photograph showing the effect of improving collagen cells after applying 2500 IU/ g of retinol for two weeks.
- Figure 12 is a photograph showing the effect of improving collagen cells after applying specimen 9 prepared in Example 2 for two weeks.
- Figure 13 is a photograph showing the effect of improving collagen cells after applying the extracts of Example 1 for two weeks.
- Example 1 Preparation and separation of ginsenoside Rg3 RS by acidic hydrolysis 2 kg of ginseng was minced into pieces and extracted under reflux by using
- 20(S)-ginsenoside and 20(R)-ginsenoside Rg3 were separated by varying the solubility toward water (polarity). It was verified that so prepared ginsenoside Rg3 comprising stereoisomers are superior in proliferating fibroblasts, expediting collagen biosynthesis and elastin synthesis, enhancing skin immunity, functions as oxidants and healing skin wounds, thus being capable of preventing and improving skin wrinkles.
- Example 2 Change in the amount of ginsenoside Rg3 and the ratio of RS isomers
- the structure of 20(S)-ginsenoside Rg3 is shown in Formula 1.
- the amounts of 20(S)-ginsenoside Rg3 and the ratios are shown in Table 1.
- Example 1 Continuous skin irritation test was performed by using about 350 g of Hartley Guinea pig.
- the extract powder of Example 1 was dissolved in butylene glycol to provide 5% solution, and 0.1 mL of the solution was open-coated on the left abdomen of the pig one time a day for 4 weeks (6 times a week). Abnormalities were observed every day, and skin irritation of the final product (Example 1) was evaluated based on the result by comparing with the positive control group, which was coated with 2% sodium lauryl sulfate solution.
- human patch test was performed by coating the extract of Example 1 on the back of 30 healthy male adults, followed by attaching the coated region for 48 hours. Skin irritation was observed twice, i.e., 2 hours and 72 hours after removing the patch.
- photo patch test was performed by attaching the patch for 24 hours and, at
- the region was irradiated with DERMARAY UV-A ray (BLB 10 etc.) for 7 minutes at a distance of 20 cm. Specimen was attached on the back for 2 hours and the rash response was determined 10 minutes after removing the specimen.
- Example 1 the extract of Example 1 comprising ginseng-derived ginsenoside
- Rg3 was verified to be very stable when applied to the skin.
- Human normal fibroblast cells were dispensed in 96-well micro plate so that each well contains 5000 cells, and cultured in DMDM (Dulbeccos Modified Eagles
- the groups treated with the final product of Example 1 and the specimen of Example 2 showed maximum 98% of fibroblast proliferation, i.e., much improved in fibroblast proliferation without toxicity.
- the amount of (20S)-ginsenoside Rg 3 is preferred to be within 40-80 wt% and the ratio is 100%, and more preferably the amount of ginsenoside Rg 3 is 60 wt% and the ratio of the S-form isomer is about 100%.
- Human normal fibroblast was dispensed in 96-well microplate for cell culture, and cultured under the condition of 37 °C, 5% CO2 for 24 hours in the medium comprising 5% FBS (fetal bovine serum), followed by washing with PBS
- FBS fetal bovine serum
- the medium comprising cultured fibroblast and 1% FBS was treated with specimen 9, which showed good cell proliferation effects in
- the medium was added with 30 ⁇ g/mL of L[2,3,4,5-H]fluorine 5 ⁇ Ci, ascorbic acid, and cultured under the condition of 37 0 C, 5% CO2 for 24 hours.
- the medium was divided into two fractions, and only one of them was treated with type 1 collagenase. After protein was precipitated by adding 5% TCA (trichloroacetic acid), the amount of collagen produced by the radioactive difference of the fractions was measured.
- TCA trifluoroacetic acid
- Human normal fibroblast was added in 96-well microplate for cell culture, and cultured for 24 hours. The medium was treated with 1-10 ⁇ M of specimen and cultured for 2 days. The amount of elastin secreted by fibroblast was measured by using fastin elastin assay kit, and the values amended with cell number or protein amount are provided in Table 4. Table 4. Effect of proliferating elastin
- Example 1 and Example 2 show similar effects of collagen biosynthesis promotion depending on the amount of ginsenoside Rg3 and the ratio of S-form isomer.
- Experimental Example 4 Effect of enhancing skin immunity
- the effect of skin immunity enhancement varies widely depending on the amount of ginsenoside Rg3, and specimen in Example 2 showed the highest enhancement effect.
- Lipid peroxidation caused by lipoxygenase was inhibited by the extract of Example 1 and the specimen of Example 2. The degree of inhibition was measured, and vitamin C was used as a positive control group.
- Lipid peroxidation inbition (%) ⁇ x lOO Absorbance ⁇ negative control
- Example 1 and specimen 6, 9 & 12 were verified to be superior to the positive control group (Vitamin C) in inhibiting skin ageing.
- Lotions comprising the extracts herein are prepared in Prescription Examples 5-7 with their contents shown in Table 8.
- Solution(2) was moved to an emulsifying tank under vacuum, and solution(l) was also transferred to the emulsifying tank, followed by emulsification at 3500 rpm for 5 minutes.
- Creams comprising the extracts herein are prepared in Prescription
- Pre-weighed ingredients 1-12 were placed in a heatable oily-phase tank, and dissolved with stirring at 75 0 C.
- Pre-weighed ingredients 13-18 were placed in an aqueous-phase tank, and dissolved with stirring at 75 0 C.
- Hydrogel patch comprising the extracts herein was prepared in Prescription Examples 11-13, as shown in Table 10.
- the obtained hydrogel was uniformly coated on siliconated polyester film (1 m x 1 m, 700 g/m 2 ) by using a coating machine equipped with an applicator gap, and laminated with nonporous polyethylene non-woven fabric.
- the multi-layered laminates were double-cut into an appropriate size for application on face or under eyes, and packed in laminated films of paper, polyethylene and aluminum.
- the wrinkle-induced eighty mice were divided into eight groups, and six groups were treated with extract (Ex. 1) and specimen 3, 6, 9, 12 and 15 (Ex. 15) ethanol solution (0.01%).
- One group was treated with retinol (2500 IU/g)/ethanol solution (50%) as a positive control group.
- the other group was treated with 50% ethanol aqueous solution as a negative control group.
- the separated skin of the hairless mouse was observed by using Verhoeff stain method.
- the wrinkle-induced eighty mice were divided into eight groups, and six groups were treated with extract (Ex. 1) and specimen 3, 6, 9, 12 and 15 (Ex. 15) ethanol solution (0.01%).
- One group was treated with retinol (2500 IU/g)/ethanol solution (50%) as a positive control group.
- the other group was treated with 50% ethanol aqueous solution as a negative control group.
- the separated skin of the hairless mouse was observed by using Masson trichrome stain method.
- Creams (0.01 % of the specimen in Prescription Examples 8-10 with various ginsenoside Rg3 quantity), creams (0.01% of Centella asiatica), creams according to Comparative
- Prescription Example 1 were coated on the wounds once a day (0.5 g each time) for 6 days. After the rats were euthanized, skins around the wounds were separated to provide three samples per each test animal (width: 2 cm).
- Creams comprising the extracts herein were verified to be superior in healing wounds compared with the positive control group.
- the aforementioned four creams were applied to the skin below eyes twice a day (in the morning and before sleep) for 8 weeks.
- the improvement was evaluated by using questionnaires (Table 15) and image analysis.
- the test subjects could select one of four degrees of improvement (i.e. no, low, medium and much).
- Image analysis was performed by preparing replica of the skin around the eyes after sufficient skin stabilization under a constant condition of 22 0 C with relative humidity of 50%. Surface was measured by using an image analyzer system, based on which a relative change of wrinkles was obtained.
- Wrinkles were observed to decrease down to 30% or less in their density when the creams of Prescription Examples herein were used.
- the effect of skin wrinkle improvements varies depending on the amount ginseng-derived ginsenoside Rg3 herein and the ratio of stereoisomers.
- the effects of proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds may be maximized by controlling the amount of 20(S)-ginsenoside Rg3 to 40-80 wt% and as the purity of S isomer increase up to 100%, thus completed the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mechanical Engineering (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a cosmetic composition for preventing and improving skin wrinkles comprising 20(S)-ginsenoside Rg3, and more particularly to a cosmetic composition comprising 20(S)-ginsenoside Rg3, which is superior in proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent and improve skin wrinkles.
Description
COSMETIC COMPOSITION CONTAINING (20S)-GINSENOSIDE Rg3 FOR PREVENTING AND IMPROVING SKIN WRINKLES
TECHNICAL FIELD The present invention relates to a cosmetic composition for preventing and improving skin wrinkles comprising 20(S)-ginsenoside Rg3, and more particularly to a cosmetic composition comprising 20(S)-ginsenoside Rg3, which is superior in proliferating fibroblasts, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent and improve skin wrinkles.
RELATED PRIOR ART
Vitamin A (retinol) and retinyl palmitate are commonly used as cosmetic compounds for preventing and improving skin wrinkles. However, cosmetics comprising these compounds may easily deteriorate with time, and may also cause serious skin irritation when they are penetrated or absorbed into the skin exceeding their effective amounts. Thus, there is a need for developing a new compound having superior effects in improving skin wrinkles, drug stability and safety on skin.
Panax Ginseng (briefly 'Ginseng' hereinafter) is a medicinal herb belonging to Araliaceae family, which has been widely used in oriental medicine and also folk remedies. The ginseng is largely divided into three different kinds according to the status as green, white and red ginseng. White ginseng is prepared by removing rootlets of green ginseng (i.e. undried ginseng) followed by drying under the sun. Red ginseng is prepared by steaming the white ginseng. Saponin in ginseng is known to have an anti-oxidizing effect by promoting secretion of catecholamine in adrenal gland and inhibiting lipid peroxidation, along with other effects of protecting against radioactive rays, preventing abnormalities or micronuclei caused by alkylating agents, and lowering mutations in culturing cells.
According to a WTO's report, main active ingredients of ginseng are saponin ginsenosides. More specifically, green ginseng, white ginseng and red ginseng commonly contains 18 compounds of Ro, Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, Rhi, 2OgIc-Rf, Q-R1 and N-R1 as active ingredients. However, 4 compounds of Malonyl-Rbi, Malonyl-Rb2, Malonyl-Rcand and Malonyl-Rd are contained only in green ginseng and white ginseng, while 8 compounds of Rs1, Rs2, Rg3(S), Rh2, N-R4, Rg2(R), Rh1(R) and Rh4 are contained only in red ginseng.
According to the structure of saponin aglycon, ginseng saponin may be divided into panaxadiol-type ginsenosides (Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd and Rg3)/ ginsenosides (Re, Rf, Rgi and Rg2) and oleanolic acid-type ginsenosides. Ginseng roots comprise 48-60% of panaxadiol-type saponin, 30-35% of panaxatriol-type saponin and small quantity of oleanolic acid-type saponin.
One of minor ginsenosides, Rg3, is produced during the process of steaming ginseng. A few patents have already disclosed that Rg3 has activities of inhibiting cancer cell metastasis, inhibiting platelet aggregation, inducing vasorelaxation, decreasing tolerance to anticancer drugs, inhibiting experimental liver damage and antithrombotic activity. However, the pharmaceutical activities in the aforementioned patents were restricted to orally administered Rg3, and there has been no report about the activities of topically applied Rg3 for improving skin wrinkles.
In general, ginsenoside Rg3 is extracted and separated from ginseng by extracting crude saponin with an organic solvent and condensing the crude saponin, followed by separation with silica gel or repeated purification with preparative liquid chromatography. However, the extracts also comprise saponin compounds in ginsenoside Rg family, having very similar molecular weight and physiochemical properties, which remains in small quantity even after the final purification. Further, the yield of ginsenoside Rg3 is not so high and the repeated purification process for high purity requires a considerable amount of time and cost. The
biotransformation process using acidic and basic hydrolysis and glycosidase still bring us other problems such as complexity in purification process and remnant solvents.
The glycosidic bonds on the structurally unstable ginsenoside aglicone C-20 position are easily cleaved by hydrolysis by performing heating and steaming ginseng thus expediting brown change, and C-20(S) and C-20(R) isomers may be produced as hydroxyl group causes inversion equilibrium. Thus, characteristic components (Rh1, Rh2, Rs1, Rs2, Rg3, and Rgs), called as minor ginsenosides, may be extracted by heating or steaming ginseng. Further, ginsenoside Rg3, a prosapogenin, is contained more than 50 times of that in green ginseng or white ginseng.
The present inventors found that ginsenoside Rg3 has an activity of improving skin wrinkles, and filed a patent application claiming cosmetic composition comprising ginsenoside Rg3 (KR patent application no. 2003-65882). In addition, the skin improvement may be further accomplished by controlling the amount of ginsenoside Rg3 and the ratio of SR isomers to a specific range.
Specifically, the present inventors found that the effects of proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds vary depending on the amount of ginsenoside Rg3 and the ratio of 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3. More specifically, the present inventors found the aforementioned effects may be maximized by controlling the amount of 20(S)-ginsenoside Rg3 to 40-80 wt% and as the purity of S isomer increase up to 100%, thus completing the present invention.
SUMMARY OF INVENTION
Therefore, in an embodiment of the present invention there is provided a cosmetic composition for preventing or improving skin wrinkles, which comprises
20(S)-ginsenoside Rg3.
DETAILED DESCRIPTION
The present invention relates to a cosmetic composition for preventing or improving skin wrinkles, which comprises 20(S)-ginsenoside Rg3 as active ingredient.
Hereunder is provided a detailed description of the present invention. The present invention relates to a cosmetic composition comprising 20(S)-ginsenoside Rg3, which is superior in proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent or improve skin wrinkles.
The skin improvement effect varies depending on the amount of ginsenoside Rg3 and the ratio of 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3, which are prepared from ginseng by acidic hydrolysis extraction method.
The purity of ginsenoside Rg3 and the ratio of the RS isomers may be controlled by repeating silica gel column chromatography (chloroform : methanol : distilled water = 9:3:1). Specifically, the amount of ginsenoside Rg3 may be controlled in the range of 20-95 wt%. Further, the present inventors verified that the effects of proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds, thus enabling to effectively prevent and improve skin wrinkles, may be maximized by controlling the amount of 20(S)-ginsenoside Rg3 to 40-80 wt% and using nearly 100% pure S isomer.
Thus, the amount of 20(S)-ginsenoside Rg3 is preferred to be in the range of 40-80 wt %. The effects are weakened when the amount is below 40 wt%, whereas the amount of above 80 wt% would incur high cost during the extraction and purification.
Meanwhile, the side effect of the ginseng-derived ginsenoside Rg3 is lower than any other synthetic material, and the skin toxicity test also showed that the extract herein has no harmful effect on the skin.
Therefore, the ginseng-derived ginsenoside Rg3, when applied to cosmetics, may be formulated into skin softeners, astringents, lotions, essence, creams, gels, packs, soaps, essence sheets, hydrogel patches or masks. The ginseng-derived ginsenoside Rg3 is preferred to be comprised in the amount of 0.000001-20.0 wt% with respect to the total cosmetic composition. The aforementioned effects may not be obtained when the amount is below 0.000001 wt%, however, when the amount is above 20 wt% the effect of improvement may not be satisfactory considering the increase in the amount and the formulation may be unstable.
BRIEF DESCRIPTION OF DRAWINGS
Figure 1 is a HPLC result of 20(S)-ginsenoside Rg3 prepared in Example 1. Figure 2 is a photograph of skin of hairless mouse after inducing artificial wrinkles.
Figure 3 is a photograph showing the effect of improving wrinkles after applying 2500 IU/ g of retinol for two weeks.
Figure 4 is a photograph showing the effect of improving wrinkles after applying 0.01 % of specimen 9 prepared in Example 2 for two weeks.
Figure 5 is a photograph showing the effect of improving wrinkles after applying 0.01% of the extracts of Example 1 for two weeks.
Figure 6 is a photograph showing the effect of improving elastic fiber after applying negative control group for two weeks. The black stripe is elastic fiber. Figure 7 is a photograph showing the effect of improving elastic fiber after applying 2500 IU/ g of retinol for two weeks.
Figure 8 is a photograph showing the effect of improving elastic fiber after applying specimen 9 prepared in Example 2 for two weeks.
Figure 9 is a photograph showing the effect of improving elastic fiber after applying the compound prepared in Example 1 for two weeks.
Figure 10 is a photograph showing the effect of improving collagen cells after applying a negative control group for two weeks. The blue part is collagen, the dark brown is cell nucleus, and the red is cytoplasm/ muscle/ keratin.
Figure 11 is a photograph showing the effect of improving collagen cells after applying 2500 IU/ g of retinol for two weeks.
Figure 12 is a photograph showing the effect of improving collagen cells after applying specimen 9 prepared in Example 2 for two weeks. Figure 13 is a photograph showing the effect of improving collagen cells after applying the extracts of Example 1 for two weeks.
EXAMPLES
The present invention is described in greater detail with reference to the accompanying Examples. The examples herein are meant only to illustrate the present invention, and they should not be construed as limiting the scope off the claimed invention.
Example 1: Preparation and separation of ginsenoside Rg3 RS by acidic hydrolysis 2 kg of ginseng was minced into pieces and extracted under reflux by using
70% methanol, which is 5-10 times the weight of the ginseng, at 60-80 0C for 5 hours. The extracts were concentrated under reduced pressure at 50 0C and 368 g of ginseng extracts were obtained. This extracts were dissolved in 5 L of distilled water and washed with 2 L of n-hexane three times. The aqueous layer was extracted three times with 2 L of n-butanol, thereby obtaining 214 g of butanol fraction. The butanol fraction was dissolved in 1 L of methanol while heating, and macerated to remove the precipitates. Then, 1.2 g of a mixture of 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3 was obtained by performing silica gel column
chromatography (chloroform : methanol : distilled water = 9:3:1). After suspending this mixture in 24 mL of methanol while heating and removing precipitates by cooling the suspension, the remnant liquid was concentrated under reduced pressure. 576 mg of concentrates was dissolved in 20 mL of pyridine and ice-cooled with addition of 20 mL of acetic anhydride, followed by stirring at room temperature for 5 hours. The products were extracted two times with 100 mL of ethyl acetate and washed with 100 mL of 5% chloric acid and distilled water three times, respectively. The ethyl acetate fraction was concentrated under reduced pressure and 341 mg of concentrates were applied to silica gel column chromatography (dichloromethane : ethyl acetate = 8:2). 238 mg of the separated 20(S)-ginsenoside Rg3 peracetate was dissolved in 40 mL of mixture of 5% chloric acid and methanol and stirred at room temperature for 3 hours. The solution added with 100 mL of distilled water was concentrated under reduced pressure at 35 0C to remove methanol, was further extracted with 50 mL of butanol three times. The butanol fraction was concentrated under reduced pressure and applied to silica gel chromatography (chloroform : methanol : distilled water = from 9:3:1 to 4:3:1 to increase polarity), thereby obtaining 158 mg of ginsenoside Rg3 (50±1.0 %).
Further, 20(S)-ginsenoside and 20(R)-ginsenoside Rg3 were separated by varying the solubility toward water (polarity). It was verified that so prepared ginsenoside Rg3 comprising stereoisomers are superior in proliferating fibroblasts, expediting collagen biosynthesis and elastin synthesis, enhancing skin immunity, functions as oxidants and healing skin wounds, thus being capable of preventing and improving skin wrinkles.
The purity of ginsenoside Rg3 may be increased by repeating purification and separation with silica gel column chromatography (chloroform : methanol : distilled water = 9:3:1), and the ratio of RS isomers may also be controlled.
Example 2: Change in the amount of ginsenoside Rg3 and the ratio of RS isomers
The final products of Example 1 was applied to repeated separation and purification with silica gel column chromatography (chloroform : methanol : distilled water = from 9:3:1 to 4:3:1), where the polarity was gradually increased, thereby obtaining a mixture of 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3 with a different ratio.
The structure of 20(S)-ginsenoside Rg3 is shown in Formula 1. The amounts of 20(S)-ginsenoside Rg3 and the ratios are shown in Table 1.
Formula 1
Table 1. Amounts of Ginsenoside Rg3 and Ratios of RS isomer
Conditions for liquid chromatography analysis
(i) Column: J'sphere ODS-80H(250 x 4.6 mm LD, S-4 μm,YMC)
(ii) UV absorbance: at 205 nm
(iii) Mobile phase (Gradient system)
(iv) Flow rate: 1 mL/min
Reference Example 1: Toxicity Test
(1) Single dose toxicity study by intravenous and oral administration Single dose toxicity study was performed by applying intravenous and oral administration to a 5-week-old Wistar male rat. 50 mg/kg of final product (Example 1) and 100 mg/kg of specimen 1-15 (Example 2) were intravenously administered and 200 mg/kg of the ginsenoside Rg3 was orally administered.
Neither death nor abnormality was observed within 14 days after the administration, thus verifying the safety of the extracted powder prepared in Examples.
(2) Repeated dose toxicity study via oral administration for 3 months Repeated dose toxicity study was performed by applying oral administration to a 5-week-old Sprague Dawley male rat for 3 months. 100 mg/kg of the final product of Example 1 and specimen 1-15 of Example 2 were orally administered every day for 3 months. General conditions were observed every day, and weight was measured at the intervals of 7 days. Quantitative and qualitative investigations of urine and hematological examination at the end of administration, postmortem observation and long-term weight measurement showed no change due to the administration of the extract powder prepared in Examples, thus verifying their safety.
Reference Example 2; Skin irritation test
(1) Primary skin irritation test
Primary skin irritation test was performed by using white rabbit (New Zealand). Hairs (3 cm x 10 cm) in left and right regions of spine were removed, and each region was divided into two, thus having a total of four test regions. Right top and left bottom regions were stuck by 18-gauge syringe to provide #-shaped wound, the other two regions were left unhurt. The final product was dissolved in butylene glycol to provide 20% solution, and 0.5 niL of the solution was absorbed in two sheets of 2.5 cm x 2.5 cm lint. Two additional sheets of lint were absorbed only with butylene glycol. The prior lints and the latter lints were attached to the right and left regions, respectively, and it was observed if there was any abnormality at 24, 48 and 72 hours after attachment.
As a result, no skin abnormality such as rubefaction and edema was observed in both the wound and unhurt regions.
(2) Continuous skin irritation test
Continuous skin irritation test was performed by using about 350 g of Hartley Guinea pig. The extract powder of Example 1 was dissolved in butylene glycol to provide 5% solution, and 0.1 mL of the solution was open-coated on the left abdomen of the pig one time a day for 4 weeks (6 times a week). Abnormalities were observed every day, and skin irritation of the final product (Example 1) was evaluated based on the result by comparing with the positive control group, which was coated with 2% sodium lauryl sulfate solution.
As a result, no skin irritation was observed by the repeatedly coated final product of Example 1.
(3) Human patch test
According to the standard issued by Japanese Patch Test Study group, human patch test was performed by coating the extract of Example 1 on the back of 30 healthy male adults, followed by attaching the coated region for 48 hours. Skin irritation was observed twice, i.e., 2 hours and 72 hours after removing the patch.
Further, photo patch test was performed by attaching the patch for 24 hours and, at
2 hours after removing the patch, the region was irradiated with DERMARAY UV-A ray (BLB 10 etc.) for 7 minutes at a distance of 20 cm. Specimen was attached on the back for 2 hours and the rash response was determined 10 minutes after removing the specimen.
As a result, no skin irritation was observed by repeated coating the extract of
Example 1. Thus, the extract of Example 1 comprising ginseng-derived ginsenoside
Rg3 was verified to be very stable when applied to the skin.
Experimental Example 1: Effect of proliferating fibroblast
Human normal fibroblast cells were dispensed in 96-well micro plate so that each well contains 5000 cells, and cultured in DMDM (Dulbeccos Modified Eagles
Media) comprising fetal bovin serum at 37 0C for 24 hours. The medium was
diluted ten times with the extract of Example 1 and the specimen of Example 2, and cultured at 37 0C for 3 days. Each well was added with 30 μL of 0.2% MTT (3-(4/5-dimethylthiazole-2-yl)-2/5-diphenyltetrazolum bromide) solution, and cultured for 4 hours. After removing the medium, each well was added 100 μL of DMSO (dimethyl sulfoxide) solution, and shaken for 10 minutes. Absorbance of the upper fraction was measured at 570 ran by using a microplate reader. After the results of the treated and the control groups were compared, the values of cell proliferation were calculated by applying Equation 1 as provided in Table 2.
Equation 1
Absorbance {treated) - Absorbance {control)
Cell proliferation (%) : x 100 Absorbance {control)
Table 2
Example 2
Compared to untreated negative control group, the groups treated with the final product of Example 1 and the specimen of Example 2 showed maximum 98% of fibroblast proliferation, i.e., much improved in fibroblast proliferation without toxicity. This verifies that cell proliferation effect improves as the amount ginseng-derived ginsenoside Rg3 and the ratio of the S-form isomer comes close to 100%. Specifically, for the enhancement of the cell proliferation effect, the amount of (20S)-ginsenoside Rg3 is preferred to be within 40-80 wt% and the ratio is 100%, and more preferably the amount of ginsenoside Rg3 is 60 wt% and the ratio of the S-form isomer is about 100%.
Experimental Example 2: Effect of biosynthesis of collagen
Human normal fibroblast was dispensed in 96-well microplate for cell culture, and cultured under the condition of 37 °C, 5% CO2 for 24 hours in the medium comprising 5% FBS (fetal bovine serum), followed by washing with PBS
(phosphate buffer saline). The medium comprising cultured fibroblast and 1% FBS was treated with specimen 9, which showed good cell proliferation effects in
Examples 1 and 2; specimens 7 and 8 in the same amount as that of specimen 9; and specimens 3, 6, 12 and 1, which have the same composition but with different
amount so that they can be 1, 5, 10 μM, respectively. The medium was added with 30 μg/mL of L[2,3,4,5-H]fluorine 5 μCi, ascorbic acid, and cultured under the condition of 37 0C, 5% CO2 for 24 hours. The medium was divided into two fractions, and only one of them was treated with type 1 collagenase. After protein was precipitated by adding 5% TCA (trichloroacetic acid), the amount of collagen produced by the radioactive difference of the fractions was measured.
By comparing with the untreated negative control group, the collagen biosynthesis effect of each specimen was evaluated and converted into the values of the relative collagen biosynthesis (RCB) of the experimental groups along with the positive control group treated with vitamin A (retinol). The values of increase in the relative collagen biosynthesis were provided in Table 3.
Table 3
* Example 2
Compared to the vitamin A-treated group, the collagen biosynthesis was promoted when the amount of ginsenoside Rg3 was about 40-80 wt% and the ratio of S-form isomer approached 100% (Examples 1 & 2; specimen 6, 9, 12 & 15).
Experimental Example 3: Effect of synthesis of elastin
Human normal fibroblast was added in 96-well microplate for cell culture, and cultured for 24 hours. The medium was treated with 1-10 μM of specimen and cultured for 2 days. The amount of elastin secreted by fibroblast was measured by using fastin elastin assay kit, and the values amended with cell number or protein amount are provided in Table 4.
Table 4. Effect of proliferating elastin
* Example 2
As shown in Table 4, Example 1 and Example 2 show similar effects of collagen biosynthesis promotion depending on the amount of ginsenoside Rg3 and the ratio of S-form isomer.
Experimental Example 4: Effect of enhancing skin immunity
Hairs on the abdomen of an 8-week-old white mouse were removed, and the region was irradiated with 2.5 KJ/ m2 of UBV by using a sun lamp, thus causing contact hypersensitivity and inhibition of skin immunity. This region was coated with solution prepared by the extract of Example 1 and the specimen 6, 9 and 12 of Example 2 in 70% ethanol. After 3 days, the irradiated region was sensitized with 3% trinitrochlorobenzene, and the abdomen was coated with 1% trinitrobenzene after 5 days. Ear edema was evaluated by measuring the ear thickness of the experimental and the control groups. Skin immunity effect was calculated by using Equation 2, and the results are provided in Table 5.
Equation 2
Ear thickness {coated, irradiated) - Ear thickness (irradiated)
Skin immunity effect (%) = x 100 Ear thickness {untreated) - Ear thickness {irradiated)
Table 5
* Example 2
The effect of skin immunity enhancement varies widely depending on the amount of ginsenoside Rg3, and specimen in Example 2 showed the highest enhancement effect.
Experimental Example 5: Antioxidative Effect Test
Lipid peroxidation caused by lipoxygenase was inhibited by the extract of Example 1 and the specimen of Example 2. The degree of inhibition was measured, and vitamin C was used as a positive control group.
12 mL of sodium phosphate buffer solution (pH 6.8, 50 mM) was placed in a test tube. 0.1 mL of 0.1% (v/v) specimen solution dissolved in sodium phosphate buffer solution (50 mM) and 0.1 mL of arachidonic acid (6.6 mM, Sigma) were also added in the test tube. 0.1 mL of lipoxigenase dissolved in 50 mM sodium-phosphate buffer solution was added in each test tube, and reaction was performed at 25 °C for 10 minutes (the final concentration of specimen in each reaction solution was 50 μg/mL). For a negative control group, 0.1 mL of sodium-phosphate buffer solution (50 mM) was used instead of specimen solution. After reaction completed, 1 mL of 20% (v/v) trichloroactic acid and 2 mL of 0.67% (v/v) thiobarbituric acid was added. After boiling water bath for 10 minutes and cooling down to room temperature, the upper-layer fraction was separated by centrifugation (1800 rpm, 3 minutes), and absorbance was observed at 535 nm. Lipid peroxidation inhibition was calculated by using Equation 3, and the results were provided in Table 6.
Equation 3
Absorbance {treated)
Lipid peroxidation inbition (%) = ■ x lOO Absorbance {negative control)
Table 6
* Example 2
Example 1 and specimen 6, 9 & 12 were verified to be superior to the positive control group (Vitamin C) in inhibiting skin ageing.
Prescription Examples 1-4; Preparation of Cosmetics (beauty wash solution)
Beauty wash solutions comprising the extracts herein are prepared in Prescription Examples 1-4 with their contents shown in Table 7.
Table 7
Preparation method
(1) Pre-weighed ingredients 2, 3 & 4 were dissolved in distilled water 1 at room temperature, thus providing solution 1.
(2) Pre-weighed ingredients 5, 6, 7, 8 & 9 were admixed and added in solution 1, thus providing solution 2.
(3) Ingredient 10 and the final product and specimen prepared in Examples 1 and 2, respectively, were dissolved in solution 2 followed by stirring and filtration, thereby obtaining beauty wash solutions.
Prescription Example 5-7: Preparation of Lotion
Lotions comprising the extracts herein are prepared in Prescription Examples 5-7 with their contents shown in Table 8.
Table 8
(1) Pre-weighed ingredients 1-12 were placed in a heatable oily-phase tank, and dissolved with stirring at 75 0C.
(2) Pre-weighed ingredients 13-18 were placed in an aqueous-phase tank, and dissolved with stirring at 75 0C.
(3) Solution(2) was moved to an emulsifying tank under vacuum, and solution(l) was also transferred to the emulsifying tank, followed by emulsification at 3500 rpm for 5 minutes.
(4) 1% solution of the ingredients 19-20 was injected into the emulsifying tank, uniformly admixed at 2500 rpm. The solution was vacuumed while removing bubbles, and cooled to 55 °C under agitation at 25 rpm.
(5) Pre-weighed extracts in Examples were dissolved in ethanol at room temperature and uniformly admixed with pre-weighed perfume in the emulsifying tank. The solution was cooled to 30 °C and lotion was prepared.
Prescription Example 8-10 and Comparative Prescription Example 1: Preparation of Cream
Creams comprising the extracts herein are prepared in Prescription
Examples 8-10, and those without including the extract were prepared in Comparative Prescription Example 1, as shown in Table 9.
Table 9
Preparation method
(1) Pre-weighed ingredients 1-12 were placed in a heatable oily-phase tank, and dissolved with stirring at 75 0C.
(2) Pre-weighed ingredients 13-18 were placed in an aqueous-phase tank, and dissolved with stirring at 75 0C.
(3) The solution(2) was moved to an emulsifying tank under vacuum, and the solution(l) was also transferred to the emulsifying tank, followed by emulsification at 3500 rpm for 5 minutes.
(4) 1% solution of the ingredients 19-20 was injected into the emulsifying tank, uniformly admixed at 2500 rpm. The solution was vacuumed while removing bubbles, and cooled to 55 0C under agitation at 25 rpm.
(5) Pre-weighed extracts in Examples were dissolved in ethanol at room temperature and uniformly admixed with pre-weighed perfume in the emulsifying tank. The solution was cooled to 30 0C and cream was prepared.
Prescription Example 11-13; Preparation of hydrogel patch
Hydrogel patch comprising the extracts herein was prepared in Prescription Examples 11-13, as shown in Table 10.
Table 10
Preparation method
(1) Pre-weighed ingredients 1-6 were placed in a dissolving tank and uniformly stirred at room temperature, to provide viscous liquid. Ingredients 7-9 were further dissolved at room temperature and added into the dissolving tank, followed uniform stirring.
(2) Ingredients 10-14 were dissolved at 60 0C and admixed with ingredients 15-16. A small amount of the mixture was injected into the dissolving tank each time, thus producing gel .
(3) The obtained hydrogel was uniformly coated on siliconated polyester film (1 m x 1 m, 700 g/m2) by using a coating machine equipped with an applicator gap, and laminated with nonporous polyethylene non-woven fabric. The multi-layered laminates were double-cut into an appropriate size for application on face or under eyes, and packed in laminated films of paper, polyethylene and aluminum.
Experimental Example 6: Induction of artificial wrinkles on hairless mouse by using squalane-OOH method
1 L of squalane was irradiated with UVA at a maximum strength of 30 J/m2/sec for 4 weeks. The irradiated squalane was admixed with 1 L of methanol in a shaker at 2,000 rpm for 2 hours. Upper-layer fraction was separated by centrifugation at 2,000 rpm for 3 minutes, thereby obtaining squalane-OOH. The oxidized squalane was diluted with ethanol to the ratio of 1:3, and this wrinkle-inducing solution was coated on the skin of 8-week-old hairless mouse twice a day for 6 weeks (10 μL each time).
The extracts and specimen herein were coated for 2 weeks and the wrinkle improvement is shown in Figures 3-5.
Experimental Example 7: Promotion of elastin synthesis observed by Verhoeff stain method
After applying the specimen herein to wrinkle-induced hairless mouse, the effect of elastin synthesis promotion was observed by elastin stain method. The wrinkle-induced eighty mice were divided into eight groups, and six groups were treated with extract (Ex. 1) and specimen 3, 6, 9, 12 and 15 (Ex. 15) ethanol solution (0.01%). One group was treated with retinol (2500 IU/g)/ethanol solution (50%) as a positive control group. The other group was treated with 50% ethanol aqueous solution as a negative control group. After 2-week treatments, the separated skin of the hairless mouse was observed by using Verhoeff stain method.
The improvements were shown in Figures 7-9 as compared with the negative control group in Figure 6. The extract (Ex. 1) and the specimen 9 in Ex. 2) were verified to be superior in promoting elastin synthesis to retinol in the positive control group.
Experimental Example 8; Promotion of collagen synthesis observed by Masson trichrome stain method
After applying the specimen herein to a wrinkle-induced hairless mouse, the effect of collagen synthesis promotion was observed by collagen stain method.
The wrinkle-induced eighty mice were divided into eight groups, and six groups were treated with extract (Ex. 1) and specimen 3, 6, 9, 12 and 15 (Ex. 15) ethanol solution (0.01%). One group was treated with retinol (2500 IU/g)/ethanol solution (50%) as a positive control group. The other group was treated with 50% ethanol aqueous solution as a negative control group. After a 2- week treatment, the separated skin of the hairless mouse was observed by using Masson trichrome stain method.
The improvements were shown in Figures 11-13 as compared with the negative control group in Figure 10. The extract (Ex. 1) and the specimen 9 in Ex. 2) were verified to be superior in promoting collagen synthesis to retinol in the positive control group.
Experimental Example 9: Wounds healing effect in rats
Hairs on the back of 8-week-old Wistar male rats were removed, and the skin on the back was cut with a scalpel under an anesthesia and satured. Creams (0.01 % of the specimen in Prescription Examples 8-10 with various ginsenoside Rg3 quantity), creams (0.01% of Centella asiatica), creams according to Comparative
Prescription Example 1 were coated on the wounds once a day (0.5 g each time) for 6 days. After the rats were euthanized, skins around the wounds were separated to provide three samples per each test animal (width: 2 cm).
Tensile strength was measured, and the relative results compared with Comparative Prescription Example 1 were provided in Table 11.
Table 11
Creams comprising the extracts herein were verified to be superior in healing wounds compared with the positive control group.
Experimental Example 10; Effect of human skin wrinkle improvement Effect of human skin wrinkle improvement was observed in fifteen healthy women, who are 30-45 years old, by using the creams of Prescription Examples 8, 9 & 10 and the creams of Comparative Prescription Example 1.
The aforementioned four creams were applied to the skin below eyes twice a day (in the morning and before sleep) for 8 weeks. The improvement was evaluated by using questionnaires (Table 15) and image analysis. The test subjects could select one of four degrees of improvement (i.e. no, low, medium and much). Image analysis was performed by preparing replica of the skin around the eyes after sufficient skin stabilization under a constant condition of 22 0C with relative humidity of 50%. Surface was measured by using an image analyzer system, based on which a relative change of wrinkles was obtained.
Table 12
Wrinkle improvement was remarkable with Prescription Examples herein. Especially, cream of Prescription Examples showed noticeable skin improvement as
compared with Comparative Prescription Example 1 according to more than 70% of the test subjects.
Table 13
Wrinkles were observed to decrease down to 30% or less in their density when the creams of Prescription Examples herein were used.
INDUSTRIAL APPLICABILITY
As set forth above, the effect of skin wrinkle improvements varies depending on the amount ginseng-derived ginsenoside Rg3 herein and the ratio of stereoisomers. Especially, the effects of proliferating fibroblast, promoting collagen biosynthesis and elastin synthesis, enhancing skin immunity, and functioning as antioxidants and healing skin wounds may be maximized by controlling the amount of 20(S)-ginsenoside Rg3 to 40-80 wt% and as the purity of S isomer increase up to 100%, thus completed the present invention.
Claims
1. A cosmetic composition for preventing and improving skin wrinkles, wherein said composition comprises 20(S)-ginsenoside Rg3.
2. The cosmetic composition of claim 1, wherein the amount of said 20(S)-ginsenoside Rg3 is contained in the amount of from 40 to 80 wt% with respect to that of ginseng extract powder.
3. The cosmetic composition of claim 1, wherein said composition further comprises 20(R)-ginsenoside Rg3, wherein the ratio of the 20(S)-ginsenoside Rg3 and the 20(R)-ginsenoside Rg3 is 10:0-5:5.
4. The cosmetic composition of claim 1, wherein the 20(S)-ginsenoside Rg3 is separated from ginseng by acidic hydrolysis.
5. The cosmetic composition of claim 1, wherein the amount of said 20(S)-ginsenoside Rg3 is contained in the amount of from 0.000001 to 20 wt% with respect to the amount of the total cosmetic composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050036846A KR20060114774A (en) | 2005-05-02 | 2005-05-02 | Cosmetic composition containing (20s)-ginsenoside rg3 for preventing and improving skin wrinkles |
KR10-2005-0036846 | 2005-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006118364A1 true WO2006118364A1 (en) | 2006-11-09 |
Family
ID=37308138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2005/002298 WO2006118364A1 (en) | 2005-05-02 | 2005-07-18 | COSMETIC COMPOSITION CONTAINING (20S)-GINSENOSIDE Rg3 FOR PREVENTING AND IMPROVING SKIN WRINKLES |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20060114774A (en) |
WO (1) | WO2006118364A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140126892A (en) * | 2013-04-24 | 2014-11-03 | (주)아모레퍼시픽 | External composition for skin containing Ginsenoside Rg3 |
CN106420459A (en) * | 2016-10-10 | 2017-02-22 | 广州今盛美精细化工有限公司 | Ginseng water live essence, preparation method thereof and facial mask containing same |
CN106795546A (en) * | 2014-05-16 | 2017-05-31 | 汇德生物科技股份有限公司 | Ginsenoside M1 is used to suppress the purposes of kidney fibrosis |
CN107636145A (en) * | 2014-09-30 | 2018-01-26 | Rna公司 | Prepare the wherein method for the microorganism formulation that aglycon accumulates in cell and the microorganism formulation produced by this method |
TWI627972B (en) * | 2013-05-10 | 2018-07-01 | 花王股份有限公司 | Bath preparation composition |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101133739B1 (en) * | 2009-04-07 | 2012-04-09 | 건국대학교 산학협력단 | A Method for Preparing Acid Hydrolyzed White Ginseng Extracts Having High Content of Gingenoid Rg3 |
KR101416140B1 (en) * | 2012-11-15 | 2014-07-08 | 주식회사 코리아나화장품 | Topical Composition For Promoting Lipid Biosynthesis Comprising Ginsenosides Rg3 As Active Ingredient |
KR20180000379A (en) * | 2016-06-22 | 2018-01-03 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | Composition for enhancing immune response comprising ginsenoside F1 |
-
2005
- 2005-05-02 KR KR1020050036846A patent/KR20060114774A/en not_active Application Discontinuation
- 2005-07-18 WO PCT/KR2005/002298 patent/WO2006118364A1/en active Application Filing
Non-Patent Citations (3)
Title |
---|
KIM S. ET AL.: "Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 296, no. 2, 16 August 2002 (2002-08-16), pages 247 - 254, XP003003537 * |
POPOVICH D.G. ET AL.: "Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line", ARCH. BIOCHEM. BIOPHYS., vol. 406, no. 1, 1 October 2002 (2002-10-01), pages 1 - 8, XP002998587 * |
RHIM H. ET AL.: "Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng modulate Ca2+ channel currents in rat sensory neurons", EUR. J. PHARMACOL., vol. 436, no. 3, 2 February 2002 (2002-02-02), pages 151 - 158, XP003003536 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140126892A (en) * | 2013-04-24 | 2014-11-03 | (주)아모레퍼시픽 | External composition for skin containing Ginsenoside Rg3 |
KR102021463B1 (en) * | 2013-04-24 | 2019-09-16 | (주)아모레퍼시픽 | External composition for skin containing Ginsenoside Rg3 |
TWI627972B (en) * | 2013-05-10 | 2018-07-01 | 花王股份有限公司 | Bath preparation composition |
CN106795546A (en) * | 2014-05-16 | 2017-05-31 | 汇德生物科技股份有限公司 | Ginsenoside M1 is used to suppress the purposes of kidney fibrosis |
CN107636145A (en) * | 2014-09-30 | 2018-01-26 | Rna公司 | Prepare the wherein method for the microorganism formulation that aglycon accumulates in cell and the microorganism formulation produced by this method |
US10676708B2 (en) | 2014-09-30 | 2020-06-09 | Rna Inc. | Method for preparing microbial preparation and microbial preparation produced by the same |
CN107636145B (en) * | 2014-09-30 | 2021-08-20 | Rna公司 | Method for producing microbial preparation in which aglycone is accumulated in cell and microbial preparation produced by the method |
EP3202910B1 (en) * | 2014-09-30 | 2022-07-06 | Rna Inc. | Method for preparing microbial preparation in which aglycone accumulates in cells, and microbial preparation prepared thereby |
CN106420459A (en) * | 2016-10-10 | 2017-02-22 | 广州今盛美精细化工有限公司 | Ginseng water live essence, preparation method thereof and facial mask containing same |
Also Published As
Publication number | Publication date |
---|---|
KR20060114774A (en) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006118364A1 (en) | COSMETIC COMPOSITION CONTAINING (20S)-GINSENOSIDE Rg3 FOR PREVENTING AND IMPROVING SKIN WRINKLES | |
EP1327434B1 (en) | Nanoemulsion comprising metabolites of ginseng saponin and a skin-care composition for anti-aging containing the same | |
CN101184473B (en) | Composition for use in the solubilisation of hydrophobic active agents | |
JP2005298505A (en) | Method for promoting percutaneous absorption of pheum palmatum extract using high-pressure emulsification technology and whitening skin lotion composition prepared by using the same | |
EP1648403B1 (en) | Slimming cosmetic composition comprising cafestol or kahweol | |
JP4091824B2 (en) | Skin preparation | |
JP3226700B2 (en) | Whitening agent and skin external preparation | |
JP2003300858A (en) | Skin care preparation | |
US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
CN107158086A (en) | With the skin care/therapeutic combination for alleviating itch effect | |
JP2006241036A (en) | Anti-aging cosmetic | |
JP2001163718A (en) | Sebum secretion inhibitor and preparation for external use for skin | |
KR100465976B1 (en) | Nanoemulsion having Ginsenoside F1 by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof | |
JPH0859450A (en) | External preparation for skin | |
JP2007077089A (en) | Skin-beautifying composition | |
KR20030094523A (en) | Microemulsion comprising metabolites of ginseng saponin as effective component and preparation method, and skin care compositions for antiaging agent utilizing thereof | |
JP2003160463A (en) | Skin care preparation | |
JP2003183175A (en) | alpha-MSH INHIBITOR ORIGINATING FROM TEA EXTRACT AND WHITENING AGENT, ANTI-AGING AGENT AND MMP-1 PRODUCTION INHIBITOR CONTAINING THE SAME, AND SKIN CARE PREPARATION CONTAINING THESE | |
KR20160099417A (en) | Nanocarrier and Skin External Composition Comprising the Same | |
KR20160081176A (en) | Skin external composition for moisturing skin or whitening skin comprising catechins and panaxydol | |
JP2000239145A (en) | Anti-allergic agent, beautifully whitening agent and skin cosmetic | |
JPH11246424A (en) | Tyrosinase inhibitor and its production | |
JP2002053427A (en) | Collagen production accelerator and estrogenic agent and skin cosmetic | |
KR20030060018A (en) | Microemulsion having Compound K by nano-emulsion technology, and skin care and pharmaceutical compositions for external applications utilizing thereof | |
KR20050029556A (en) | Herbal extracts having anti-wrinkle effect and their preparation methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05761287 Country of ref document: EP Kind code of ref document: A1 |